Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer

To determine the maximum-tolerated dose (MTD) and the recommended dose (RD) of paclitaxel administered weekly with a fixed dose of cisplatin, and to assess the toxicity and activity of this combination, we conducted a phase I/II trial in patients with advanced non-small-cell lung cancer (NSCLC). In...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, N, Kudoh, S, Mukohara, T, Yamauchi, S, Yamada, M, Kawaguchi, T, Nakaoka, Y, Hirata, K, Yoshikawa, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409643/
https://www.ncbi.nlm.nih.gov/pubmed/15026799
http://dx.doi.org/10.1038/sj.bjc.6601672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409643/
https://www.ncbi.nlm.nih.gov/pubmed/15026799
http://dx.doi.org/10.1038/sj.bjc.6601672

Ejemplares similares